RHUMBLINE ADVISERS

Position in LXEO — Lexeo Therapeutics, Inc.

CIK 1115418 BOSTON, MA

Position in LXEO

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$371,510

-$42,240 QoQ

Shares Held

79,809

+10.7% QoQ

Ownership

0.097%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#58

of 141 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 18% Shared 0% None 82%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. LXEO ranks #206 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	396,380	$196,893,837
2	REGN	Regeneron Pharmaceuticals, Inc.	157,794	$98,390,870
3	MRNA	Moderna, Inc.	809,853	$56,714,005
4	ALNY	Alnylam Pharmaceuticals, Inc.	165,579	$49,844,246
5	INCY	Incyte Corp	428,533	$48,578,500
6	RVMD	Revolution Medicines, Inc.	226,008	$42,326,778
7	ROIV	Roivant Sciences Ltd.	1,178,789	$41,717,342
8	JAZZ	Jazz Pharmaceuticals plc	163,018	$39,282,447

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$371,510	79,809	+10.7%	Shares	Sole	2026-08-12
2026-03-31	$413,750	72,082	+3.9%	Shares	Sole	2026-05-12
2025-12-31	$688,834	69,369	+118.4%	Shares	Sole	2026-02-13
2025-09-30	$210,912	31,764	-0.7%	Shares	Sole	2025-11-06
2025-06-30	$128,599	31,990	+6.0%	Shares	Sole	2025-08-12
2025-03-31	$104,766	30,192	+19.8%	Shares	Sole	2025-05-29
2024-12-31	$165,796	25,197	+19.6%	Shares	Sole	2025-05-29
2024-09-30	$190,472	21,070	+57.7%	Shares	Sole	2024-11-12
2024-06-30	$214,246	13,357	+37.3%	Shares	Sole	2024-08-01
2024-03-31	$152,566	9,730	—	Shares	Sole	2024-05-09
No filing history on record for this holder in this stock.